Related Experiment Video
Updated: May 22, 2026
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Perceptions of young people living with HIV and caregivers in Botswana on analytical treatment interruption studies:
Catherine K Koofhethile1,2,3,4, Poloko Kebaabetswe1, Ontlametse T Choga1
1Botswana Harvard Health Partnership, Gaborone, Botswana.
Background:
Current research suggests that post-treatment HIV control may be possible for some people following antiretroviral treatment (ART) interruption. Although closely monitored analytic treatment interruption (ATI) studies can be performed safely and are crucial to determine who may no longer require ART, currently it is unknown how acceptable these studies will be in Botswana.
Aim:
To determine the knowledge, attitudes and acceptability of ATI-inclusive studies in Botswana.
Methods:
We employed a non-randomized purposive design to recruit study participants. We conducted face-to-face open-ended interviews with 12 young people living with HIV and 8 caregivers, 8 healthcare providers and 4 community advocates in Gaborone and Palapye.
Results:
Thirty-two (32) participants consented to be interviewed. The median age of young people living with HIV was 29 years. All young people living with HIV indicated that they were on ART and acknowledged the benefits of being on ART. All young people living with HIV were unaware of ATIs, whereas 6 out of 8 caregivers, 6 out of 8 healthcare providers and 2 out of 4 community advocates had never heard of ATIs. Most participants found ATI research to be acceptable and believed that it would be beneficial provided there were adequate risk mitigations in place.
Conclusions:
ATI studies were acceptable to both young people living with HIV and their caregivers. There was limited knowledge about ATI, highlighting a need to inform communities and health care providers on the scientific aspects of ATI and HIV cure research.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
01:10Retrovirus Life Cycles
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...